[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.173.45. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 9, 1952

HORMONAL MANAGEMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA

Author Affiliations

New York
From the Experimental Hematology Section of the Department of Clinical Investigation, the Hormone Chemotherapy Section of the Division of Experimental Chemotherapy of the Sloan-Kettering Institute of Cancer Research, and the Head and Neck Division of the Department of Surgery of the Memorial Center for Cancer and Allied Diseases, New York. Alfred P. Sloan Fellow, Sloan-Kettering Institute (Dr. Koch).

JAMA. 1952;149(15):1376-1380. doi:10.1001/jama.1952.02930320016006
Abstract

The purpose of this paper is to report a new method for reducing the tendency to hemorrhage in patients with hereditary hemorrhagic telangiectasia (Osler-Rendu disease). Although the periods of observation of the patients treated were of short duration, the longest having been just over one year, the results to date of writing were of sufficient interest to merit a preliminary report.

DEFINITION  The term hereditary hemorrhagic telangiectasia was first advocated by Hanes1 in 1909. He defined this disease as a "hereditary affection manifesting itself in localized dilatations of the capillaries and venules forming distinct groups of telangiectases which occur upon the skin of the face, nasal and buccal mucous membranes, and give rise to profuse hemorrhage either spontaneously or as a result of trauma." The cardinal findings for the establishment of the diagnosis of this disease are contained in Hanes' definition: (1) the hereditary tendency toward the disease, (2)

×